Park et al. published in 2011 that low-dose CPX plus dendritic cell vaccine derived from irradiated tumor cells improved the control of tumor growth kinetics, reduced intratumoral regulatory cells, and reduced levels of immune suppressive IL-10 and TGF-β in a model of mammary carcinoma [53]. Here, TGFB1 is linked to neoplasm.